News | May 07, 2026
Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum
The standout story remains Wegovy, particularly its new oral formulation
The standout story remains Wegovy, particularly its new oral formulation
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
Conceptualized as an aggregator platform it integrates existing programme systems through an API-based federated architecture
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
Subscribe To Our Newsletter & Stay Updated
